Enumeral Biomedical Reports That Its Novel Class Of Anti-PD-1 Antibodies Elicits Higher T Cell Activation In Ex Vivo Human Assays Than Currently Marketed Anti-PD-1 Antibodies

Assays Performed Using Lung Biopsy-Derived Tumor Infiltrating Lymphocytes Show Improved Restoration of T Cell Function Using Enumeral’s Anti-PD-1 Antibody

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral researchers have demonstrated greater functional activity of its novel class of anti-PD-1 antibodies (as measured by restoration of T cell function in cell-based assays) when compared to conventional anti-PD-1 antibodies that disrupt PD-1 interaction with PD-L1. Enumeral’s potentially allosteric antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.

“We have accomplished a number of important goals in our recent experiments, most critical of which was to demonstrate the differentiated activity of our novel class of anti-PD-1 antibodies”

Enumeral’s researchers measured the ability of anti-PD-1 antibodies to restore interferon gamma production by tumor infiltrating lymphocytes (TILs) derived from tumor biopsy specimens obtained from patients diagnosed with lung cancer. Compared to the use of currently marketed anti-PD-1 antibodies, experiments with Enumeral’s anti-PD-1 antibody resulted in approximately 50% to 100% higher interferon gamma production by the TILs.

“We have accomplished a number of important goals in our recent experiments, most critical of which was to demonstrate the differentiated activity of our novel class of anti-PD-1 antibodies,” said Cokey Nguyen, Ph.D., Enumeral’s Vice President of Research and Development. “We employed the widely used protocol of pre-administering CD3 and CD28 to activate the TILs, and yet in certain of the samples we saw very little baseline T cell function prior to antibody treatment. Anti-PD-1 blockade was critically needed in concert with TIL activation to observe enhanced T cell function, underscoring just how immunosuppressed the tumor microenvironment can be.”

“Our recent progress has confirmed the potential of employing ex vivo human approaches to measure the function of, and functional responses elicited by, novel immuno-oncology drug candidates. We believe such analyses will provide a strong basis for further drug development decisions, as well as supporting regulatory submission as our programs advance toward clinical development,” commented Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral.

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral’s stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include, among others, the risks that (a) Enumeral’s expectations regarding market acceptance of the Company’s business in general and the Company’s ability to penetrate the antibody discovery and development fields in particular, as well as the timing of such acceptance, (b) Enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies, (c) the scope, validity and enforceability of Enumeral’s and third party intellectual property rights, (d) Enumeral’s ability to raise capital when needed and on acceptable terms and conditions, (e) Enumeral’s ability to comply with governmental regulation, (f) the intensity of competition, (g) changes in the political and regulatory environment and in business and fiscal conditions in the United States and overseas and (h) general economic conditions.

More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Help employers find you! Check out all the jobs and post your resume.